Work Here?
Industries
AI & Machine Learning
Healthcare
Company Size
201-500
Company Stage
Series C
Total Funding
$203.6M
Headquarters
New York City, New York
Founded
2012
Aetion creates software solutions that help life sciences companies, regulators, and purchasers make informed decisions using real-world evidence (RWE). Their platform analyzes real-world data to provide insights into the effectiveness and safety of medical innovations, enabling clients to generate clinical insights that were previously difficult to obtain. Aetion differentiates itself by focusing on maximizing the return on investment for real-world data, offering quick insights that facilitate critical decision-making. The company's goal is to expedite patient care by equipping life sciences companies with the necessary tools for data-driven decisions.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$203.6M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Medical, dental, & vision insurance
Free membership to OneMedical
FSA
4% 401(k) match
Commuter benefits for parking & transit
Unlimited PTO
Paid parental leave
Wellness stipend
Company activities
Datavant is acquiring Aetion, a competitor in the real-world data sector, as reported exclusively by Endpoints News. This acquisition will lead to Datavant doubling its life sciences team. Further details are expected to be announced by Datavant on Thursday.
Aetion's industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering organizations to unlock the full potential of their data and achieve measurable impactNEW YORK, March 31, 2025 /PRNewswire/ -- Aetion , the global leader in real-world evidence (RWE) technology and analytics, today announced the availability of its Aetion® Evidence Platform (AEP) in Amazon Web Services (AWS) Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS. This launch removes implementation barriers, simplifies procurement and enables life sciences organizations, payers and regulators to harness scalable, cloud-based evidence generation with the security and reliability of AWS.AEP empowers organizations to analyze real-world data (RWD) to generate transparent, reproducible and regulatory-grade evidence for decision-making in drug development, market access, policy and pricing. By leveraging AWS Marketplace, Aetion streamlines access to its platform and reliable, fit-for-purpose solutions tailored to meet each organization's specific objectives, as well as accelerating time-to-insights and ensuring compliance with global regulatory standards.Aetion relies on AWS as its core infrastructure, leveraging services such as Amazon Bedrock to power its artificial intelligence and machine learning (AI/ML)-driven capabilities in order to unlock hidden insights about patient populations and translate scientific intent to results. These technologies enhance AEP's ability to process complex RWD at scale, enabling sophisticated hypothesis generation and analysis automation for evidence generation."The availability of AEP in AWS Marketplace underscores our commitment to providing scalable, high-impact solutions that help organizations make real-world data work for them," said Jay Podence, senior vice president of Commercial Partnerships at Aetion. "By integrating with AWS, we offer our new and existing customers a seamless path to deploy and scale real-world evidence studies with enhanced efficiency and security. This is the first step in our vision to expand our collaboration with AWS to bring more value to our customers
NEC's CVC fund, NEC Orchestrating Future Fund, has invested in Aetion, Inc., a U.S. company providing a medical data analysis platform. This investment aims to enhance collaboration in utilizing real-world data (RWD) and real-world evidence (RWE) for drug development. Aetion's platform, Aetion Evidence Platform, is used globally by pharmaceutical companies and healthcare organizations to improve decision-making. NEC and Aetion will explore synergies to streamline drug development processes.
NEC Orchestrating Future Fund (NOFF) has invested in Aetion, a leader in real-world evidence technology. NEC and Aetion will collaborate to use Japanese electronic health records for drug development via Aetion's Substantiate® application. This partnership aims to enhance drug development efficiency and regulatory pathways. Aetion's platform uses AI and privacy-preserving techniques to transform real-world data into evidence, supporting personalized medicine and next-gen healthcare.
Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the appointment of Kevin Riley as president.
Find jobs on Simplify and start your career today
Industries
AI & Machine Learning
Healthcare
Company Size
201-500
Company Stage
Series C
Total Funding
$203.6M
Headquarters
New York City, New York
Founded
2012
Find jobs on Simplify and start your career today